美國生技企業Axiom Biosciences擬採港股首發戰略 引領跨境融資新範式

總部位於美國聖地牙哥的創新生物科技企業Axiom Biosciences（前身為Cytonus）日前正式公佈資本市場規劃，宣佈將打破常規，計劃以香港聯合交易所作為首次公開募股（IPO）的首要資本市場，並適時推進美國納斯達克二次上市。此舉標誌著美國本土生物科技企業首次將港股作為主要上市基地，為全球跨境醫療資本佈局開創全新路徑。

臨床數據突破 奠定資本化里程碑

Axiom Biosciences的核心研發管線聚焦於前沿細胞治療領域，主打以沃頓膠來源間充質幹細胞（MSCs）技術為核心的創新療法，主要適應症涵蓋新生兒腦室內出血及缺氧缺血性腦病（HIE）。臨床數據顯示，其I期臨床試驗中9名受試新生兒完成兩年期隨訪，死亡率為0%，顯著優於該疾病自然病程首年約46%的歷史死亡率。此項強勁的臨床數據與安全性驗證，不僅滿足港交所生物科技公司上市規則（18A章）的核心要求，更為企業全球化估值確立了堅實的基本面支撐。

雙向資本協同與策略考量

本次逆向登陸策略背後，驅動邏輯涵蓋監管契合度與亞洲資本協同：

法規適配與融資窗口：港交所針對未盈利生物科技企業設立的靈活上市機制，高度契合創新型研發企業在I期臨床完成後的資金對接需求。

產業鏈與股東結構：公司早期融資獲得國際與亞洲頂尖資本青睞，兼具亞太地區強大的產業鏈資源整合優勢，有助於加速產品的商業化落地。

階梯式估值成長路徑：透過率先在亞太旗艦資本市場建立流動性與估值基準，能有效聚合國際機構投資人共識，為後續對接北美資本市場奠定估值優勢。

行業戰略啟示

此項資本規劃充分體現港交所生命科學板塊國際競爭力的顯著提升。隨著亞洲資本市場對全球前沿醫療創新項目的吸引力不斷增強，港股正逐步轉型為全球生物科技企業的核心融資樞紐，並有望成為未來更多美資創新藥企赴亞太融資的可複製範本。

投資風險提示：本文內容僅供參考，不構成任何投資建議。生技醫療產業具備研發周期長、臨床試驗不確定性高及監管審批嚴格等特點，投資人應審慎評估相關潛在風險，自負盈虧。

Axiom Biosciences Pioneers Cross-Border Funding Paradigm with Primary Hong Kong IPO Strategy

Axiom Biosciences, a clinical-stage biopharmaceutical enterprise headquartered in San Diego, California (formerly Cytonus), has announced a strategic restructuring of its capital markets roadmap. Breaking conventional listing norms, the company intends to pursue an initial public offering (IPO) on the Stock Exchange of Hong Kong (SEHK) under Chapter 18A regulations as its primary listing venue, followed by a subsequent secondary listing on the Nasdaq Stock Market. This transaction marks a precedent-setting shift for a U.S.-domiciled biotechnology firm choosing Hong Kong as its foundational public market entry point.

Clinical Validation and Capitalization Milestones

Axiom Biosciences’ core therapeutic pipeline centers on advanced cell therapy, specifically Wharton's jelly-derived mesenchymal stem cells (MSCs) targeting neonatal intraventricular hemorrhage and hypoxic-ischemic encephalopathy (HIE). Clinical data from its Phase I trial demonstrated a 0% mortality rate among nine neonatal subjects over a two-year follow-up period, outperforming the historical first-year mortality rate of approximately 46% associated with the natural disease progression. This robust safety and efficacy profile successfully satisfies the core listing criteria under the SEHK Chapter 18A framework, establishing a solid fundamental valuation baseline for global institutional syndication.

Strategic Drivers and Cross-Border Synergies

The rationale underpinning this reverse-listing trajectory incorporates regulatory optimization and regional capital integration:

Regulatory Fit and Liquidity Access: The SEHK listing regime for pre-revenue biotechnology enterprises provides a transparent regulatory pathway tailored to corporate milestones following Phase I clinical completion.

Shareholder and Industrial Synergy: Supported by strategic early-stage financing led by Asian institutional capital and collaborative development with regional partners, the company leverages robust supply chain networks and regional market access to accelerate commercialization.

Tiered Valuation Strategy: Establishing an initial liquidity benchmark and institutional valuation anchor within an international Asian financial hub enhances global investor consensus ahead of subsequent North American market penetration.

Industry Implications

This strategic capital allocation highlights the growing competitiveness of Hong Kong’s healthcare and life sciences equity platform. As regional capital markets increase their appeal for global biomedical innovations, the SEHK is solidifying its position as a primary fundraising nexus for international enterprises, potentially serving as a scalable listing template for peer U.S. biotechnology firms seeking cross-border capital deployment.

Investment Disclaimer: This material is for informational purposes only and does not constitute investment advice, an endorsement, or a solicitation to buy or sell any securities. The biotechnology and life sciences sector involves substantial risks, including extended R&D cycles, clinical trial uncertainties, and stringent regulatory approvals. Investors should perform independent due diligence and assess their risk tolerance prior to making investment decisions.

https://www.ivy-service.com

alinson@ivy-service.com